GSK Expands Scope of RSV Vaccine Patent Suit on Pfizer’s Abrysvo

GSK Plc added allegations involving a newly issued patent to its 15-month-old federal lawsuit seeking lost profits and royalties for Pfizer Inc.’s Abrysvo, a vaccine for respiratory syncytial virus that competes with GSK’s Arexvy.

GSK alleges that Abrysvo or its “biological active substances” infringe US Patent No. 12,139,512, which was issued Nov. 12 and covers specific types of proteins the vaccine uses to help the body recognize and fight the virus, according to GSK’s second amended complaint filed Thursday in the US District Court for the District of Delaware. The new patent expires in May 2032, about a year ...